The following articles provided pharmacokinetic and pharmacodynamic observations with a novel prodrug of propofol. We have subsequently been informed that the assay used for these analyses is not valid (see this issue: Shah A, Mistry B, Gibiansky E, Gibiansky L: Fospropofol assay issues and impact on pharmacokinetic and pharmacodynamic evaluation. Anesthesiology 2008; 109:937). As such, the reader should interpret the drug concentration data and modeling determined from such data with caution.
Fechner J, Ihmsen H, Hatterscheid D, Schiessl C, Vornov JJ, Burak E, Schwilden H, Schüttler J: Pharmacokinetics and clinical pharmacodynamics of the new propofol prodrug GPI 15715 in volunteers. Anesthesiology 2003; 99:303–13
Fechner J, Ihmsen H, Hatterscheid D, Jeleazcov C, Schiessl C, Vornov JJ, Schwilden H, Schüttler J: Comparative pharmacokinetics and pharmacodynamics of the new propofol prodrug GPI 15715 and propofol emulsion. Anesthesiology 2004; 101:626–39
Gibiansky E, Struys MMRF, Gibiansky L, Vanluchene ALG, Vornov J, Mortier EP, Burak E, Van Bortel L: AQUAVAN® injection, a water-soluble prodrug of propofol, as a bolus injection: A phase I dose-escalation comparison with DIPRIVAN® (part 1): Pharmacokinetics. Anesthesiology 2005; 103:718–29
Struys MMRF, Vanluchene ALG, Gibiansky E, Gibiansky L, Vornov J, Mortier EP, Van Bortel L: AQUAVAN® injection, a water-soluble prodrug of propofol, as a bolus injection: A phase I dose-escalation comparison with DIPRIVAN® (part 2): Pharmacodynamics and safety. Anesthesiology 2005; 103:730–43
